Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases
J WolfJosef S Smolen

Abstract

Methotrexate is transported into the cell by the reduced folate carrier (RFC) and out of the cell by members of the multidrug resistance protein family (MRP). Transport proteins may affect the therapeutic efficacy of this drug in patients with rheumatoid arthritis. To investigate the potential benefit of the presence of RFC and the absence of functional MRP for the efficacy of methotrexate treatment. The study involved 163 patients (116 female, 47 male; mean age 59.5 years) on methotrexate (mean weekly dose 12.2 mg). RFC was determined using reverse transcriptase polymerase chain reaction, and MRP function by flow cytometry, using a calcein acetoxymethylesther/probenecid assay. Clinical response to methotrexate was evaluated by the EULAR response criteria and the ACR 20% improvement criteria. The clinical data were obtained at the beginning of methotrexate treatment and at the time of blood sampling during ongoing therapy. Patients were divided into four groups according to the presence (+) or absence (-) of RFC and functional (f) MRP. fMRP+/RFC+ and fMRP-/RFC- patients more often had good EULAR response rates (60%, p = 0.014, and 53%, p = 0.035, respectively) in comparison with the fMRP-/RFC+ group (29%); fMRP+/RFC- patients h...Continue Reading

References

Jan 1, 1990·Annual Review of Nutrition·G B Henderson
Dec 1, 1988·Zhonghua nei ke za zhi·J L Yang
Mar 28, 1985·The New England Journal of Medicine·M E WeinblattD E Trentham
Dec 30, 1983·The American Journal of Medicine·R T Hoffmeister
Aug 26, 1998·Rheumatic Diseases Clinics of North America·J M Kremer
Aug 17, 2000·Journal of the National Cancer Institute·P BorstJ Wijnholds
Apr 27, 2001·Toxicology Letters·D SchrenkH M Kauffmann
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Xavier DeclèvesJean-Michel Scherrmann
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·Maciej J Zamek-GliszczynskiKim L R Brouwer

❮ Previous
Next ❯

Citations

Jan 5, 2007·Nature Clinical Practice. Rheumatology·Joost W van der HeijdenGerrit Jansen
May 19, 2010·Joint, Bone, Spine : Revue Du Rhumatisme·Jean-Francis MaillefertUNKNOWN Réseau Rhumato Study Group
Sep 17, 2013·Translational Research : the Journal of Laboratory and Clinical Medicine·Azza A K El-SheikhFrans G M Russel
Dec 31, 2015·Diagnostic Pathology·Tamás MicsikIstván Peták
Jan 28, 2006·Mayo Clinic Proceedings·Carl Turesson, Eric L Matteson
Feb 28, 2015·Immunopharmacology and Immunotoxicology·Lorena Michele Brennan-BourdonJosé Francisco Muñoz-Valle
Mar 14, 2018·Inflammopharmacology·Mary Beth YuWilliam H R Langridge
Aug 7, 2020·Inflammopharmacology·Jun Yu, Peng Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

Joint, Bone, Spine : Revue Du Rhumatisme
Vincent GoëbOlivier Vittecoq
Joint, Bone, Spine : Revue Du Rhumatisme
Thao PhamRheumatic Diseases & Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Soci
© 2021 Meta ULC. All rights reserved